Literature DB >> 8932263

Determinants of chronic renal allograft rejection in cyclosporine-treated recipients.

S M Flechner1, C S Modlin, D P Serrano, D A Goldfarb, D Papajcik, B Mastroianni, M Goormastic, A C Novick.   

Abstract

We analyzed the development of chronic rejection in 511 kidney-only renal transplants in 507 patients between July 1987 and November 1994. A database was established for recipients > or = 18 years old who received cyclosporine-based immunosuppression and demonstrated graft survival for a minimum of 12 months. The 347 recipients of cadaver transplants (67.9%) and 164 recipients of live donor transplants (32.1%) were followed for 12 to 102 months (mean 51 months). Chronic rejection was diagnosed in 124 transplants (24%), with a mean time to diagnosis of 23+/-18 months (range 3-92). Risk factors were identified in a multivariate analysis using the Cox model. The impact of the timing and severity of rejection episodes was analyzed in a univariate model. The presence of chronic rejection resulted in decreased (P=0.0001) 5-year graft survival for both cadaver graft (83.7% vs. 58.2%) and live donor graft (93.2% vs. 53.1%) recipients. Significant variables for the development of chronic rejection included an acute rejection episode (P=0.0001), a black recipient (P=0.0006), donor age > or = 50 years (P=0.006), and a serum creatinine level >2.0 mg/dl by 6 months after transplantation. Severity of rejection measured by peak serum creatinine or posttreatment return to baseline was not related to chronic rejection. However, acute rejection episodes lasting for more that 5 days (P=0.03) or occurring after 6 months (P=0.001) did influence time to chronic rejection. In addition, mismatching for donor-recipient race was a significant (P=0.008) risk factor for recipients of cadaver grafts. We conclude that acute rejection is the most significant risk factor for chronic rejection, and the long-term fate of grafts may be determined as early as the first 6 months. Racial matching of donor-recipient pairs may be useful to minimize chronic rejection risk. Future advances that diminish the incidence and severity of acute rejection may have the greatest impact on long-term survival.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8932263     DOI: 10.1097/00007890-199611150-00009

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Fibrosis with inflammation at one year predicts transplant functional decline.

Authors:  Walter D Park; Matthew D Griffin; Lynn D Cornell; Fernando G Cosio; Mark D Stegall
Journal:  J Am Soc Nephrol       Date:  2010-09-02       Impact factor: 10.121

2.  Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin.

Authors:  T Zolfino; M A Heneghan; S Norris; P M Harrison; B C Portmann; I G McFarlane
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 3.  Everolimus: a review of its use in renal and cardiac transplantation.

Authors:  Christopher Dunn; Katherine F Croom
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK.

Authors:  Phil McEwan; Simon Dixon; Keshwar Baboolal; Pete Conway; Craig J Currie
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Chronic allograft failure in human renal transplantation: a multivariate risk factor analysis.

Authors:  A J McLaren; S V Fuggle; K I Welsh; D W Gray; P J Morris
Journal:  Ann Surg       Date:  2000-07       Impact factor: 12.969

Review 6.  Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens.

Authors:  Pierre Merville
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Cost evaluation of basiliximab treatment for renal transplant patients in Japan.

Authors:  Tomonori Hasegawa; Hidehiko Imai; Sunao Miki
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 8.  Chronic Renal Transplant Rejection and Possible Anti-Proliferative Drug Targets.

Authors:  Adnan Bashir Bhatti; Muhammad Usman
Journal:  Cureus       Date:  2015-11-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.